Search Contact

Euronext and Flandersbio celebrate the 10th edition of Knowledge for Growth

Back

Ghent - 9 May, 2014. On Thursday, May 8, 2014, FlandersBio organized the 10th edition of its annual life sciences conference Knowledge for Growth in Ghent. Over 1,100 participants and more than 130 companies rallied behind the theme of Knowledge for Growth 2014: Biotech for society 2024: what will be the key societal challenges in 2024 and how will the life sciences sector help to address them?

To celebrate the opening of the tenth edition of Knowledge for Growth, Benedikt Timmerman, CEO of therapeutic cancer vaccine developer Genticel, was invited to open the market on Euronext Brussels. Genticel has recently been admitted to listing on Euronext Brussels and Paris, and thus enjoys the strengths of both markets in the biotech sector. He was joined by Henk Joos, Managing Director of FlandersBio, Vincent Van Dessel, CEO of Euronext Brussels and Alain Baetens, Head of Listings of Euronext Brussels.

Vincent Van Dessel, CEO of Euronext Brussels, said, "The dual listing of Genticel on our French and Belgian markets is an excellent example of our leadership in biotech. Genticel is a successful French company with strong Belgian roots that fully utilizes the benefits of the exchange to reach its strategic goals”.

“Euronext Brussels is pleased to be associated with FlandersBio for the largest European Biotech Conference in Ghent” said Alain Baetens, Head of Listings of Euronext Brussels.  "It underscores our commitment to the sector and leverages on the leading sector franchise listed on Euronext Markets”.

Benedikt Timmerman, founder and CEO of Genticel, said: “As someone from Ghent, it is a real thrill to be able to celebrate Genticel’s IPO here today. The double listing in Paris and Brussels allows us to commit to our Belgian investors, operations, and partners. We now have the financial resources that we need to develop our portfolio of candidate therapeutic vaccines, which are designed to give therapeutic options to women carrying the human papillomavirus and hereby reduce the number of cases of cervix carcinoma.”

Henk Joos, Managing Director of FlandersBio, highlights the continued growth of the sector: "Meanwhile, the Flemish cluster counts 255 companies and organizations. Biotechnology has become an integral part of our daily lives. The further development of an international investment platform for our companies and the further development of a growing talent pool, are the two main objectives for FlandersBio ".
 

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With nearly 1,900 listed issuers and around €6.3 trillion in market capitalisation as of end September 2024, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2024, Euronext N.V. - All rights reserved.